Hemogenyx Pharmaceuticals PLC
Last updated September 28, 2026
Organization details
- Legal name
- Hemogenyx Pharmaceuticals PLC
- Former names
- Silver Falcon PLC
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 72110 - Research and experimental development on biotechnology
- Year founded
- 2013
- Jurisdiction of incorporation
- England and Wales
- Headquarters city
- London
- Headquarters country
- United Kingdom
- Fiscal year end
- December
Identifiers
- UK company number
- 08401609
Board of directors
-
Alexis Sandler · DirectorSince 2017
-
Marc, Feldmann · DirectorSince 2018
-
Peter Redmond · DirectorSince 2015
-
Vladislav, Sandler · DirectorSince 2017
Former directors
-
Adrian Richard Thorpe Beeston · Director2015 – 2018
-
Geoffrey Gilbert Dart · Director2013 – 2017
-
Lawrence Pemble · Director2017 – 2018
-
Robin William, Campbell · Director2017 – 2019
-
Timothy Vincent Le Druillenec · Director2014 – 2015
-
Timothy Vincent Le Druillenec · Director2017 – 2017
Board connections
1 of this board's directors also sit on 1 other board.
- via Peter Redmond
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Akanda Corp.
Nasdaq: AKAN · New Romney, United Kingdom
Organization
Akari Therapeutics plc
Nasdaq: AKTX · Tampa, United Kingdom
Organization
AstraZeneca PLC
NYSE: AZN · Cambridge, United Kingdom
Organization
Autolus Therapeutics plc American Depositary Share
Nasdaq: AUTL · London, United Kingdom
Organization
Questions about Hemogenyx Pharmaceuticals PLC
How many directors are on Hemogenyx Pharmaceuticals PLC's board?
Hemogenyx Pharmaceuticals PLC's board has 4 directors: Alexis Sandler, Marc, Feldmann, Peter Redmond and Vladislav, Sandler.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="hemogenyx-pharmaceuticals-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.